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Abstract
Mycolactones, macrolide cytotoxins, are key virulence factors of Mycobacterium ulcerans,
the etiological agent of the chronic necrotizing skin disease Buruli ulcer. There is urgent
need for a simple point-of-care laboratory test for Buruli ulcer and mycolactone represents a
promising target for the development of an immunological assay. However, for a long time,
all efforts to generate mycolactone-specific antibodies have failed. By using a protein conju-
gate of a truncated non-toxic synthetic mycolactone derivative, we recently described gener-
ation of a set of mycolactone-specific monoclonal antibodies. Using the first mycolactone-
specific monoclonal antibodies that we have described before, we were able to develop an
antigen competition assay that detects mycolactones. By the systematic selection of a
capturing antibody and a reporter molecule, and the optimization of assay conditions, we
developed an ELISA that detects common natural variants of mycolactone with a limit of
detection in the low nanomolar range. The mycolactone-specific ELISA described here will
be a very useful tool for research on the biology of this macrolide toxin. After conversion into
a simple point-of-care test format, the competition assay may have great potential as labora-
tory assay for both the diagnosis of Buruli ulcer and for the monitoring of treatment efficacy.
Author summary
The macrolide toxin mycolactone is the key virulence factor of Mycobacterium ulcerans,
the causative agent of the chronic necrotizing skin disease Buruli ulcer. Mycolactone has
cytotoxic activity and is secreted by the mycobacteria, causing tissue necrosis and immu-
nosuppression. For research on Buruli ulcer, there is urgent need for a simple tool to
quantify mycolactone. Using the first mycolactone-specific monoclonal antibodies that
we have described previously, we have optimized here an antigen competition ELISA that
detects common natural variants of mycolactone at a low nanomolar scale. Sensitivity of
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the assay is sufficient to detect the toxin in M. ulcerans culture supernatants and in the tis-
sue of experimentally infected animals. Converted into a simple point-of-care test format,
the competition assay may in future also be suitable as a diagnostic laboratory test for Bur-
uli ulcer.
Introduction
Mycobacterium ulcerans is the etiological agent of the chronic necrotizing skin disease Buruli
ulcer (BU) that primarily affects children in West and Central Africa [1]. Genomic analyses
have shown that M. ulcerans has emerged from a common ancestor with the fish pathogen
Mycobacterium marinum [2, 3] by acquisition of a virulence plasmid carrying genes that
encode polyketide-modifying enzymes and the giant polyketide synthases responsible for the
synthesis of the lipid toxin mycolactone [4]. While M. marinum occasionally causes limited
granulomatous skin lesions in humans [5], chronic M. ulcerans infections are associated with a
much more severe pathology. Mycolactone plays a key role in the chronic necrotizing patho-
genesis of BU and, in addition, analgesic and immunosuppressive effects are attributed to the
toxin [6]. There is evidence of multiple modes of action of mycolactone, including inhibition
of Sec61-mediated protein translocation, uncontrolled assembly of actin by binding to the
Wiskott-Aldrich syndrome protein (WASP) family, and induction of apoptosis through
increased expression of the pro-apoptotic regulator Bim [6, 7]. Mycolactone is an amphiphilic
molecule, prone to forming aggregates in aqueous solutions [8, 9], to binding to soluble pro-
teins [10], and to inserting into lipid bilayers [8, 11]. At an air/buffer interface, mycolactone
has been shown to have surfactant properties with an apparent surface saturation concentra-
tion of 1 μM [8].
Early case detection and rapid initiation of antibiotic treatment are currently the key ele-
ments of BU control. The disease presents in a variety of clinical manifestations, complicating
the clinical diagnosis [12]. Laboratory tests routinely used for confirmation of clinical diagno-
sis include primarily the microscopic detection of acid-fast bacilli (AFB) and M. ulcerans-spe-
cific PCR tests. While microscopy–the only diagnostic test that can currently be performed
routinely at hospital level–has limited sensitivity, PCR detecting the insertion sequence IS2404
is highly sensitive and specific [13]. However, PCR requires sophisticated laboratory infra-
structure and well-trained personnel and is not reliable without strict quality control [14]. In
resource-poor BU endemic countries, the test is only available at a few reference centres,
which poses major logistical problems. Therefore, there is urgent need for a simple and rapid
diagnostic test for BU that can be performed at local hospital level or in the field [13]. Mycolac-
tone represents an ideal target for such an assay, since it seems to be unique to M. ulcerans. A
mycolactone-specific assay may also be highly suitable for monitoring treatment efficacy and
to diagnose relapses, since mycolactone levels in the affected tissue decline during successful
specific therapy [15, 16].
Mycolactones consist of a core structure, a short C-linked upper side chain, and a longer
C5-O-linked lower acyl side chain. Geographical lineages of M. ulcerans produce different
pools of molecular variants of mycolactone, which differ in the structure of the lower polyun-
saturated side chain but are otherwise structurally conserved [17]. For the generation of myco-
lactone-specific monoclonal antibodies (mAbs), we have used a truncated synthetic
mycolactone in which the lower polymorphic side chain was replaced by a linker molecule
[18]. Therefore, the epitopes recognized by these mAbs appear to comprise determinants of
the conserved core and upper side chain. Consequently, common natural molecular species of
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mycolactone were recognized [18]. Here, our aim was to use the mAbs as antigen capture
reagents to develop an immunological assay for the quantification of mycolactones.
Materials and methods
Ethical statement
Animal experiments performed were approved by the animal welfare committees of the Can-
ton of Basel (authorization number 2375) and the Canton of Bern (authorization number
BE95/17). They were conducted in compliance with the Swiss Animal Welfare Act (TSchG),
Animal Welfare Ordinance (TSchV), and the Animal Experimentation Ordinance (TVV).
Preparation of mycolactone stock solutions
Production of synthetic mycolactones and mycolactone derivatives (Fig 1) has been described
elsewhere [7, 17, 19, 20]. All compounds were HPLC-purified.
Monoclonal antibodies
Generation of the 12 mouse mAbs designated JD5.1 to JD5.12 has been described previously
[18]. MAbs were purified from hybridoma culture supernatants by affinity chromatography
using a HiTrap Protein A HP column (GE Healthcare).
Initial competition ELISA
MaxiSorp immunoassay plates (Thermo Scientific) were coated with 100 μL mAb (10 μg/ml)
overnight at 4˚C. After washing the plate twice with PBS-0.05% Tween-20 (PBST), the wells
were blocked with SuperBlock T20 (TBS) blocking buffer (Thermo Scientific) for 1 h at 37˚C.
After another washing step, serial dilutions of the sample were made in PBST and added to the
plate (100 μL/well), and then incubated in the dark for 2 h at 37˚C. Without washing, 100 μL/
well of a 200 pg/ml solution of the reporter molecule PG-204 (Fig 1) was added to the plate
and incubated for an additional 30 min. Subsequently, plates were washed four times, and
bound PG-204 was detected using alkaline phosphatase-coupled streptavidin (SouthernBio-
tech)/para-nitrophenylphosphate (pNPP) detection after 1 h incubation at 37˚C.
Optimized competition ELISA
For assay optimization phosphate-, tris(hydroxymethyl)aminomethan (TRIS)- and triethano-
lamine (TEA)-based buffers with different concentrations of dimethyl sulfoxide (DMSO) were
compared. Furthermore, different reporter molecules, reagent concentrations, detection sys-
tems, and the use of detergents (Tween-20, Triton X-100, Triton X-114, IGEPAL, Brij 35,
CHAPSO; Sigma-Aldrich) were evaluated. Following these multiple optimization steps, a new
standard protocol was defined: MaxiSorp immunoassay plates were coated with 5 μg/ml of
mAb JD5.1 overnight at 4˚C. After washing the plate twice with PBST, the plate was blocked
with SuperBlock T20 (TBS) blocking buffer (Thermo Scientific) for 1 h at 37˚C. After another
washing step, serial dilutions of the samples in LW buffer (0.2 M TEA, pH 7.5, with 20%
DMSO) were added to the plates and incubated in the dark for 2 h at 37˚C. Without washing,
100 μL of an 80 ng/ml solution of the reporter molecule MG-161 (Fig 1) in LW buffer was
added to the plate and incubated for an additional 45 min. Subsequently, plates were washed
four times, and bound MG-161 was detected after 1 h incubation at 37˚C by horseradish per-
oxidase-coupled streptavidin (SouthernBiotech) diluted 1:5000 in PBST. Signal development
was done with 3,3’,5,5’-tetramethylbenzidine (TMB) for 5 min after which the reaction was
stopped with 0.5 M sulphuric acid.
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Binding of mAbs to reporter molecules in ELISA
NeutrAvidin-coated plates (Thermo Scientific) were coated with 1 μg/ml of the different bioti-
nylated mycolactone derivatives–MG-158, MG-160, and MG-161 (Fig 1). Each of the 12 mAbs
was serially diluted in PBST, added to the coated plates, and incubated for 2 h. After a washing
step, bound mAbs were detected using horseradish peroxidase-conjugated goat anti-mouse
IgG antibodies (SouthernBiotech) after 1 h incubation at 37˚C. Signal development was done
with TMB for 7 min after which the reaction was stopped with 0.5 M sulfuric acid.
Competition ELISA using mycolactone-coated plates
NeutrAvidin-coated plates (Thermo Scientific) were coated with 1 μg/ml of the biotinylated
mycolactone derivative MG-161 (Fig 1). A dilution series of mycolactone was prepared to
which the mAb JD5.1 was added at a fixed concentration, and both were incubated together at
37˚C for 2 hours to allow for binding. Subsequently, the mixture was transferred to the MG-
161-coated plates and incubated for 1 hour at 37˚C. Bound mAbs were detected using a sec-
ondary antibody conjugated with horseradish peroxidase (HRP), and detection was done with
TMB.
Fig 1. Structures of mycolactone A/B and of synthetic derivatives.
https://doi.org/10.1371/journal.pntd.0008357.g001
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Cultivation of M. ulcerans and analysis of secreted mycolactone
An African M. ulcerans strain (S1013) and an Australian strain (S1251) were grown at 30˚C in
BACTEC liquid culture media (Becton Dickinson). Both strains have only been minimally pas-
saged after isolation from BU lesions. For the detection of mycolactones in the bacterial culture
supernatants, 500 μl of well-grown M. ulcerans cultures were centrifuged at 13,300 x g to pellet
the bacteria, and the supernatant was filtered using sterile 0.22 μm syringe filters. The sterile-
filtered supernatants were used directly in the assay.
Analysis of M. ulcerans in infected mouse footpads
BALB/c mice, age 7–8 weeks (Janvier Labs, Le Genest-Saint-Isle, France) were inoculated in
the left hind footpad with about 5 x 103 CFU of the M. ulcerans isolate S1013 from Cameroon.
The progression of footpad swelling was tracked for 13 weeks (S1 Fig), when mice were eutha-
nized, and the footpads were collected and stored in absolute ethanol for 9 weeks. Uninfected
right hind footpads served as controls. Subsequently, the ethanol was recovered and concen-
trated by vacuum centrifugation (SpeedVac, Thermo Scientific). Footpads were minced and
homogenized in a bead-beater (Precellys MK-28R) in 1.5 ml of ethyl acetate. The supernatant
was filtered and concentrated by vacuum centrifugation. Each extract was re-suspended in
60 μl of DMSO, and half this volume was used in the assay. For the quantification of the con-
centration of mycolactone detected in the extracts, standard curves were generated with syn-
thetic mycolactone A/B and used to derive a regression equation for the determination of the
concentration in the extracts.
Results
We have tested a panel of 12 anti-mycolactone mAbs (JD5.1 –JD5.12; Table 1) described previ-
ously [18] for suitability as capturing reagent for a mycolactone-specific competition assay.
The mAbs were generated by immunization of mice with PG-203, a truncated and non-cyto-
toxic mycolactone derivative coupled to BSA via a linker replacing the C5-O-linked polyunsat-
urated acyl side chain (Fig 1), and by ELISA screening of hybridomas using PG-204 (Fig 1),
which is a biotinylated derivative of PG-203 [18]. As predicted from the structure of PG-203
Table 1. Binding of the anti-mycolactone mAbs to different reporter molecules. NeutrAvidin-coated plates were
coated with the different reporter molecules at 1 μg/ml and 3-fold dilution series of the different mAbs starting from
5 μg/ml were added and allowed to bind. Bound mAbs were detected with an HRP-conjugated secondary antibody
and TMB. Binding was graded based on the absorbance (OD) values measured at 450 nm as follows: (-) OD< 0.5, (+)
OD 0.5–1, (++) OD>1–1.5, (+++) OD> 1.5.
PG-204 MG-161 MG-158 MG-160
JD5.1 +++ +++ +++ -
JD5.2 +++ +++ - -
JD5.3 +++ +++ + -
JD5.4 +++ +++ ++ -
JD5.5 +++ +++ ++ -
JD5.6 +++ +++ + -
JD5.7 +++ +++ - -
JD5.8 +++ +++ ++ -
JD5.9 +++ +++ +++ -
JD5.10 +++ +++ +++ -
JD5.11 +++ +++ +++ +
JD5.12 +++ +++ + -
https://doi.org/10.1371/journal.pntd.0008357.t001
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and PG-204, the presence/absence or detailed structure of the C5-O-linked acyl side chain
does not affect binding of the mAbs and, since the core and upper side chain of mycolactone
are completely conserved, all tested mycolactone variants showed binding [18]. While a com-
petition ELISA format with the mAbs was initially only used to assess their fine specificity
[18], we describe here the optimization of this assay format for the detection and quantifica-
tion of mycolactones in biological samples.
Optimization of the reporter molecules
To find a potentially more suitable substitute for the initially used reporter molecule PG-204
(Fig 1) for the competition assay, we screened the panel of 12 mAbs for recognition of related
derivatives with modifications at the C20 position of the upper side chain (MG-158, MG-160,
and MG-161; Fig 1). While all mAbs showed strong binding to MG-161, which carries an
additional hydroxyl group, only one mAb showed limited binding to MG-160 carrying a bulky
p-methoxybenzyl ether group. A wide variation in binding was observed with the different
mAbs for MG-158, carrying an additional acetoxy group (Table 1). Overall, competition assays
with mAb JD5.1, which bound to both MG-158 and MG-161 (Fig 2A) showed the highest sen-
sitivity. This mAb appears to have a higher affinity for PG-204 than for mycolactone, which
explains why as little as 100 pg/ml of PG-204 can out-compete a large excess of mycolactone
for binding to the mAb [18]. We surmised that using a less tightly bound reporter molecule
would allow for lower concentrations of mycolactone to be detected in the assay. In fact, MG-
161 was found to be the best substitute for PG-204, resulting in an approximately 5-fold
increase in the assay sensitivity (Fig 2B). However, to obtain optimal sensitivity, a 400-fold
higher concentration of MG-161 than of PG-204 (40 ng/ml versus 100 pg/ml) was required.
Optimization of the ELISA conditions
We attempted to improve sensitivity of the competition assay further by reducing aggregation
of mycolactone without denaturing the mAbs used in the ELISA. While ethanol, acetonitrile,
and sodium dodecylsulphate improve the dispersion of the toxin in water [9], these solvents
Fig 2. Binding properties of mAb JD5.1. (A) Binding of mAb JD5.1 to the different reporter molecules. NeutrAvidin-coated plates were coated with the
different reporter molecules (1 μg/ml), a serial dilution of mAb JD5.1 was allowed to bind, and bound mAb was detected with an HRP-conjugated secondary
antibody. (B) Sensitivity of the JD5.1-based competition assay with PG-204 (100 pg/ml) or MG-161 (40 ng/ml) as reporter molecules. JD5.1 bound to MaxiSorp
plates was allowed to react with dilution series of mycolactone A/B for 2 hours after which PG-204 or MG-161 was added for 45 min; bound reporter was
detected with HRP-conjugated streptavidin and TMB. Experiments were done in duplicate (two separate runs on different days) and the results shown are the
mean of both runs, with error bars indicating the range.
https://doi.org/10.1371/journal.pntd.0008357.g002
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were, even in small concentrations, detrimental for the binding of the mAbs to mycolactone.
Screening of a panel of non-denaturing detergents (Tween-20, Triton X-100, Triton X-114,
IGEPAL, Brij 35, CHAPSO) at various concentrations showed that no other detergent or con-
centration out-performed 0.05%-Tween-20 previously selected for the PBS-based assay buffer
[18]. Further systematic comparisons of phosphate-, TRIS-, and TEA-based buffers with dif-
ferent concentrations of dimethyl sulfoxide (DMSO) and Tween-20 resulted in the definition
of the LW buffer, giving the highest assay sensitivity in the low nanogram scale (Fig 3). The
buffer contains 20% DMSO and 0.2 M TEA, but no detergent. TEA is commonly used in
emulsifiers to dissolve compounds that are poorly soluble in water. The sensitivity of the com-
petition assay is only slightly reduced in the presence of serum (S2 Fig).
Small additional improvements of the assay sensitivity were achieved by switching from the
alkaline phosphatase-based to the peroxidase-based antibody detection system, and by reduc-
ing the JD5.1 mAb coating concentration from 10 μg/ml to 5 μg/ml. A reversed competition
format using biotinylated mycolactone bound to NeutrAvidin plates showed a sensitivity com-
parable to that with antibody-coated plates (Fig 4).
Detection of mycolactone in biological samples
Sterile-filtered culture supernatants of an African and an Australian M. ulcerans strain both
gave positive readouts in the assay (Fig 5), demonstrating that both mycolactone A/B predomi-
nantly produced by African strains and mycolactone C predominantly produced by Australian
strains that are together responsible for>95% of reported BU ulcer cases [1] are recognized.
These supernatants were used directly in the assay without any prior lipid extraction.
Mycolactone could also be specifically detected in extracts from mouse footpads infected
with M. ulcerans. After extended storage (9 weeks) of the infected footpads in ethanol (EtOH),
most of the mycolactone was found in the ethanol extract (Fig 6A), and only traces had
Fig 3. Improved assay sensitivity upon buffer optimization. Compared is the performance of the ELISA with the
TEA-based LW buffer (0.2 M TEA with 20% DMSO) or with a PBST-based buffer (PBST with 20% DMSO). JD5.1
bound to MaxiSorp plates (coating concentration 5 μg/ml) was allowed to react with dilution series of mycolactone A/
B in PBST buffer or TEA-based buffer for 2 hours after which MG-161 (40 ng/ml) was added for 45 min; bound
reporter was detected with HRP-conjugated streptavidin and TMB. Results shown are the mean of duplicate
experiments and error bars indicate the range.
https://doi.org/10.1371/journal.pntd.0008357.g003
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remained in the footpad tissue, which was extracted with ethyl acetate (EtOAc) after homoge-
nization of the footpads (Fig 6B). No mycolactone was detected in the extracts from uninfected
control footpads (Fig 6). Using a standard curve generated with synthetic mycolactone A/B,
the amount of mycolactone in the extracts was calculated (Table 2).
Fig 4. Indirect competition ELISA format. Serial dilutions of mycolactone were mixed with fixed concentrations of
mAb JD5.1 and allowed to react for 2 h at 37˚C after which the mix was transferred to NeutrAvidin plates coated with
the target molecules MG-161 or PG-204 at 1 μg/ml. MAb bound to the plate was detected with an HRP-conjugated
secondary antibody and TMB. Results shown are the mean of duplicate experiments and error bars indicate the range.
https://doi.org/10.1371/journal.pntd.0008357.g004
Fig 5. Detection of mycolactone in culture supernatants of M. ulcerans strains. Dilution series of culture
supernatants of an African and an Australian M. ulcerans isolate, synthetic mycolactone A/B as positive control (PC),
or plain medium as negative control (NC) were made in LW buffer and allowed to react with mAb JD5.1 bound to
MaxiSorp plates for 2 hours after which MG-161 (40 ng/ml) was added for 45 min; bound reporter was detected with
HRP-conjugated streptavidin and TMB. Results shown are the mean of duplicate experiments and error bars indicate
the range.
https://doi.org/10.1371/journal.pntd.0008357.g005
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Discussion
BU control measures rely mainly on early diagnosis of cases, preferably in the WHO Category
I and II stages, and the prompt initiation of treatment. The current gold standard diagnostic
test is the highly specific and sensitive PCR assay based on the detection of the high copy num-
ber insertion sequence IS2404. The main drawback in implementing this assay for routine
diagnosis is the indispensability of well-equipped laboratories, skilled and experienced person-
nel, and rigid adherence to quality control measures. As a result, efforts have been made to
develop BU diagnostics that would be low-cost and require simple instrumentation, while still
giving results in a short time. Immunodiagnostic assays such as ELISA, which depend on the
interactions between antibodies and their corresponding antigens, are viable alternatives to
genetic test systems and are comparatively simpler to perform even at the primary healthcare
or field levels. For BU, mycolactone makes an ideal antigen for specific immunodiagnosis
given its uniqueness to the mycolactone-producing mycobacteria (MPM). Also, since the lev-
els of mycolactone in tissues are reported to decline during specific treatment [15, 16], an
assay quantifying mycolactone in BU lesions would be useful in monitoring treatment efficacy.
However, efforts to generate antibodies against this small, lipid-like, cytotoxic and immu-
nosuppressive polyketide have long been unsuccessful. Using a novel approach which involved
the use of a modified non-toxic variant of mycolactone coupled to a protein carrier to immu-
nize mice, we have recently described for the first time the generation of mAbs against myco-
lactone [18]. Here, we describe the optimization of a competition ELISA based on these mAbs
for the detection and quantification of mycolactone in biological samples. We sought to sys-
tematically optimize each step of the multi-step assay procedure, leading to modest gains per
Fig 6. Detection of mycolactone in extracts from experimentally infected mouse footpads. Extracts were prepared by vacuum-centrifugation of the ethanol
in which the footpads were stored (Fig 6A; EtOH fraction), or of the ethyl acetate in which the footpads were homogenized (Fig 6B; EtOAc fraction). Dilution
series of the extracts or synthetic mycolactone A/B were made in LW buffer and allowed to react with mAb JD5.1 bound to MaxiSorp plates for 2 hours after
which MG-161 (40 ng/ml) was added for 45 min; bound reporter was detected with HRP-conjugated streptavidin and TMB.
https://doi.org/10.1371/journal.pntd.0008357.g006
Table 2. Quantification of mycolactone in infected and uninfected mouse footpads.
Sample EtOH fraction (ng) EtOAc fraction (ng)
Mouse 1 footpad 55.9 1.0
Mouse 2 footpad 82.8 0.9
Mouse 3 footpad 53.5 1.4
Uninfected footpad 0 0
https://doi.org/10.1371/journal.pntd.0008357.t002
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step but an overall 30-fold gain in sensitivity, allowing for the detection of nanogram levels of
mycolactone in biological samples.
One key difficulty in detecting mycolactone by ELISA is its inherent hydrophobicity, largely
due to the lower acyl side chain. ELISA, by default, is designed for hydrophilic molecules, typi-
cally proteins. Special methods have to be devised for the detection of hydrophobic molecules,
such as the chloroform-ethanol coating method described for lipids [21, 22, 23]. However, we
were aiming for more facile methodologies such that the resultant assay protocol would be rel-
atively straightforward for the development of rapid diagnostic tests that can be performed in
peripheral settings. As an amphiphilic molecule, mycolactone is thought to form micelle-like
structures in aqueous solutions, with the acyl side chain sequestered within the core of these
structures [9]. We attempted to disperse these structures using a variety of methods with the
main challenge to find a solvent that would lead to improved mAb binding to the mycolactone
molecules without denaturing the mAbs used in the ELISA. While detergents are routinely
used to disperse lipid aggregates, none of the non-protein-denaturing detergents we tested led
to an improvement in the sensitivity of our assay. In contrast, using 0.2 M TEA as the ELISA
running buffer improved assay sensitivity compared to phosphate- and TRIS-based ELISA
buffers. TEA is widely used as a buffering agent with surfactant properties in consumer prod-
ucts [24, 25] and in biomedical research [25, 26, 27, 28].
Switching the reporter molecule from PG-204 to MG-161, which is less tightly bound by
the capturing mAb, also improved the overall assay sensitivity. Here, a drawback is that a
400-fold higher concentration of the synthetic mycolactone derivative is needed when switch-
ing to MG-161.
Conformational changes associated with the binding of mAbs to a plastic surface can lead
to drastic changes in their antigen binding properties [29]. Therefore, we also explored the
possibility of rearranging the assay set-up to allow the capturing mAb and mycolactone to
react in solution, rather than at a solid-liquid interface with immobilized mAb. However, we
found that this indirect competition format had no added benefits, and the need to use Neu-
trAvidin-coated plates for the coating with a biotinylated mycolactone derivative for mAb cap-
turing increases the overall costs of the assay.
The utility of the improved competition ELISA as a research tool was assessed by measuring
mycolactone concentrations directly in M. ulcerans culture supernatants and in footpads of
experimentally infected mice. The amounts found in the infected footpads (50 to 100 ng/foot-
pad) are comparable to those (49 ng/footpad) that were measured with thin-layer chromatog-
raphy at a slightly earlier time point after infection [30]. The mycolactone ELISA thus is, in its
optimized format, a valuable research tool that will allow to quantify mycolactone in large
series of biological specimens. The assay may also be suitable as a diagnostic test for BU at the
district hospital level. Reagents and assay conditions developed here may also be instrumental
for the development of a simple point-of-care diagnostic test format, such as a lateral flow
assay. While basic laboratory equipment and technical expertise is required to perform an
ELISA, a simple lateral flow assay could be performed directly with wound exudate obtained
by swabbing of ulcerative BU lesions or fine needle aspiration from closed lesions. While it has
been shown, that mycolactone is extracted from serum samples with low efficacy [31], the sen-
sitivity of the competition assay is only slightly reduced in the presence of serum. Our prelimi-
nary results indicate that no extraction with organic solvents may be required to perform these
immunological tests.
In summary, the diagnosis of BU is still problematic, and development of BU diagnostics
has not kept pace with the implementation of antibiotic treatments. Here, we describe a simple
immunoassay for the specific and sensitive detection of mycolactone in biological samples.
The generation of the first-ever described mAbs specific for mycolactone and chemical
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PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008357 June 26, 2020 10 / 13
synthesis of mycolactone derivatives suitable as reporter molecules led to the development of a
competition ELISA that we have systematically optimized here. While representing a valuable
research tool for high-throughput quantification of mycolactone, this ELISA may also have
potential as diagnostic assay for BU at district hospital level. Furthermore, the developed
reagents and protocols may also enable development of a simple point-of-care test by convert-
ing the ELISA format into a lateral flow assay.
Supporting information
S1 Fig. Time course of footpad swelling in M. ulcerans infected mice.
(TIF)
S2 Fig. Sensitivity of the assay in the presence or absence of fetal bovine serum. Dilution
series of synthetic mycolactone A/B were done in LW buffer alone or LW buffer containing
50% fetal bovine serum (FBS) were allowed to react with mAb JD5.1 bound to MaxiSorp plates
for 2 hours; plain FBS was included as negative control. Subsequently, MG-161 (40 ng/ml) was
added for 45 min, and bound reporter was detected with HRP-conjugated streptavidin and
TMB.
(TIF)
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